Abstract

The present invention relates to extracellular vesicles derived from regulatory B cells, and the use thereof in therapy.

IPC Classes  ?

• A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
• C12N 5/0781 - B cellsProgenitors thereof

Abstract

The invention describes a method for obtaining purified recombinant Adeno-Associated Virus particles (rAAV), comprising the steps of: a) performing a depth filtration of a starting material previously obtained from cells producing rAAV particles, the said starting material being selected in a group comprising a cell lysate and a culture supernatant, whereby a rAAV-containing clarified composition is provided; b) submitting the rAAV-containing clarified composition to a first step of anion-exchange chromatography on a chromatographic support wherein elution is performed by using a linear salt gradient and wherein the rAAV-containing fraction is collected, whereby a first rAAV enriched composition is provided; c) submitting the first rAAV enriched composition at least once to a second step of anion-exchange chromatography on a chromatographic support wherein elution is performed by using a linear salt gradient and wherein the rAAV-containing fraction is collected, whereby a second rAAV enriched composition is provided; d) submitting the second rAAV enriched composition to a step of tangential flow filtration, whereby purified recombinant Adeno-Associated Virus particles (rAAV) are provided.

IPC Classes  ?

• C12N 15/86 - Viral vectors
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• B01D 15/36 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
• B01D 69/02 - Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or propertiesManufacturing processes specially adapted therefor characterised by their properties

Abstract

The present invention concerns a new urinary metabolomic signature of spontaneous operational tolerance (SOT) in kidney transplant recipients/patients (KTR) showing enrichment in tryptophan-derived metabolites.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The invention relates to a dermatological composition comprising at least one polar extract of an alga of the Skeletonema genus or a photosensitizer derived therefrom, for the treatment of acne or bacterial infections; as well as a process for decontaminating a surface using a polar extract of an alga of the Skeletonema genus or a photosensitizer derived therefrom.

IPC Classes  ?

• A61K 36/02 - Algae
• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 8/9706 - Algae
• A61P 17/10 - Anti-acne agents
• A61Q 19/00 - Preparations for care of the skin

Abstract

The present invention relates to the use of a formulation comprising a phosphocalcic cement and a physical and/or ovalent hydrogel of polysaccharides for 3D printing, more particularly for bone regeneration and/or bone repair. The present invention also relates to a kit for 3D printing of bone implants comprising a phosphocalcic cement and a physical and/or covalent hydrogel of polysaccharides as well as to a method to prepare a formulation for 3D printing comprising a step of mixing a phosphocalcic cement and a physical and/or covalent liquid hydrogel precursor of polysaccharides.

IPC Classes  ?

• A61L 27/38 - Animal cells
• A61L 27/20 - Polysaccharides
• A61L 27/52 - Hydrogels or hydrocolloids
• A61L 27/54 - Biologically active materials, e.g. therapeutic substances
• A61L 27/46 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with phosphorus-containing inorganic fillers

Abstract

The present invention relates to a method for segmenting a digital image, for example to accurately segment cerebral vasculature on MRI-TOF images of a brain. The method first uses a model that imitates the perception of luminance contrasts by a human observer to accentuate a contrast between structures of interest, such as cerebral vasculature, and the image background. Then, the image is thresholded using an adaptive threshold. This enhanced segmentation method can be used to process digital images before launching further machine-implemented characterizations of the structures of interest, such as detecting and characterizing bifurcations of the cerebral vasculature for intra-cranial aneurysm prediction.

IPC Classes  ?

• G06T 7/136 - SegmentationEdge detection involving thresholding
• G06T 7/11 - Region-based segmentation
• G06T 5/00 - Image enhancement or restoration

Abstract

The present invention relates to a method for radioiodination or radioastatination of a biomolecule such as proteins and antibodies by reacting a biomolecule carrying a hetero(aryl) boronic acid group with a radioiodide or astatide salt, in the presence of a catalyst and a ligand, in a buffer solution, in order to obtain a radioiodo- or astatolabeled biomolecule. The method of the invention is thus a single step method easy to be implemented and efficient for both radioiodination and radioastatination of antibodies.

IPC Classes  ?

• C07B 59/00 - Introduction of isotopes of elements into organic compounds
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07F 5/02 - Boron compounds

Abstract

SkeletonemaSkeletonema Skeletonema or a photosensitizer derived therefrom.

IPC Classes  ?

• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61K 36/03 - Phaeophycota or phaeophyta (brown algae), e.g. Fucus
• A61P 31/04 - Antibacterial agents
• A61P 17/10 - Anti-acne agents

Abstract

The invention describes a method for obtaining purified recombinant Adeno-Associated Virus particles (rAAV), comprising the steps of: a) performing a depth filtration of a starting material previously obtained from cells producing rAAV particles, the said starting material being selected in a group comprising a cell lysate and a culture supernatant, whereby a rAAV-containing clarified composition is provided; b) submitting the rAAV-containing clarified composition to an affinity purification step, whereby a first rAAV enriched composition is provided; c) submitting the first rAAV enriched composition at least once to: c1) a step of anion-exchange chromatography on a chromatographic support wherein elution is performed by using a salt gradient, preferably a linear salt gradient, and wherein the rAAV-containing fraction is collected, whereby a second rAAV enriched composition is provided; or c2) a step of density gradient centrifugation, wherein the rAAV-containing fraction is collected, whereby a second rAAV enriched composition is provided; d) submitting the second rAAV enriched composition to a step of tangential flow filtration, whereby purified recombinant Adeno-Associated Virus particles (rAAV) are provided.

IPC Classes  ?

• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C12N 9/16 - Hydrolases (3.) acting on ester bonds (3.1)
• C12N 9/18 - Carboxylic ester hydrolases
• C12N 15/86 - Viral vectors

Abstract

The present invention relates to a method for segmenting a digital image, for example to accurately segment cerebral vasculature on MRI-TOF images of a brain. The method first uses a model that imitates the perception of luminance contrasts by a human observer to accentuate a contrast between structures of interest, such as cerebral vasculature, and the image background. Then, the image is thresholded using an adaptive threshold. This enhanced segmentation method can be used to process digital images before launching further machine-implemented characterizations of the structures of interest, such as detecting and characterizing bifurcations of the cerebral vasculature for intra-cranial aneurysm prediction.

IPC Classes  ?

• G06T 5/00 - Image enhancement or restoration
• G06T 7/11 - Region-based segmentation
• G06T 7/136 - SegmentationEdge detection involving thresholding

Abstract

6)alkyl group, —CO—NH—, and —NH—CO—, for use for the treatment of pathologies characterized by bronchoconstriction, such as asthma.

IPC Classes  ?

• A61K 31/63 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide
• A61P 11/06 - Antiasthmatics

Abstract

The present invention concerns a compound of following general formula (I): for use for treating cancer.

IPC Classes  ?

• C07D 471/04 - Ortho-condensed systems
• A61P 35/04 - Antineoplastic agents specific for metastasis
• C07D 487/04 - Ortho-condensed systems
• C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
• C07D 495/04 - Ortho-condensed systems
• C07D 513/04 - Ortho-condensed systems

Abstract

The present invention relates to a method for radioiodination or radioastatination of a biomolecule such as proteins and antibodies by reacting a biomolecule carrying a hetero(aryl) boronic acid group with a radioiodide or astatide salt, in the presence of a catalyst and a ligand, in a buffer solution, in order to obtain a radioiodo- or astatolabeled biomolecule. The method of the invention is thus a single step method easy to be implemented and efficient for both radioiodination and radioastatination of antibodies.

IPC Classes  ?

• C07B 59/00 - Introduction of isotopes of elements into organic compounds
• C07F 5/02 - Boron compounds

Abstract

Technics are known to use vessel bifurcations detection to obtain access to the detection of aneurysms. However, such technics suffer from a relatively poor accuracy. Therefore, the Applicants have developed a specific method for locating and characterizing bifurcations of a cerebral vascular tree based on a graph analysis of a three-dimensional skeleton of the tree. This enables to determine more accurately the vessel bifurcations. Such property can be used advantageously for several applications such as predicting the risk of developing an aneurysm, diagnosing an aneurysm, identifying a therapeutic target, identifying a biomarker or screening a compound.

IPC Classes  ?

• G06T 7/00 - Image analysis

Abstract

The present invention concerns a compound having the following formula (I): 6)alkyl group, and R being preferably a group having the following formula (II): for use for the treatment of cancers, such as metastatic cancers.

IPC Classes  ?

• A61P 35/00 - Antineoplastic agents
• C07C 311/29 - Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring

Abstract

+ B cells, and c) determining the risk of occurrence of chronic lung graft dysfunction in the said subject from the comparison performed at step b).

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The present invention concerns a compound having the following formula (I): wherein:- A is in particular -N(R'a)-C(=O)-R, R'a being H or a (C1-C6)alkyl group, andR being preferably a group having the following formula (II): - X is in particular chosen from the group consisting of: -SO2-N(R'b)-, R'bbeing H or a (C1-C6)alkyl group, -N(R”b)-SO2-, R”b being H or a (C1-C6)alkyl group,-CO-NH-, and -NH-CO-,for use for the treatment of cancers, such as metastatic cancers.

IPC Classes  ?

• C07C 311/21 - Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
• A61K 31/63 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide
• A61P 35/04 - Antineoplastic agents specific for metastasis
• C07C 311/44 - Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring

Abstract

The present invention concerns a compound having the following formula (I): wherein: - A is in particular -N(R'a)-C(=O)-R, R'a being H or a (C1-C6)alkyl group, and R being preferably a group having the following formula (II): - X is in particular chosen from the group consisting of: -SO2-N(R'b)-, R'b being H or a (C1-C6)alkyl group, -N(R"b)-SO2-, R"b being H or a (C1-C6)alkyl group, -CO-NH-, and -NH-CO-, for use for the treatment of pathologies characterized by bronchoconstriction, such as asthma.

IPC Classes  ?

• C07C 311/21 - Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
• C07C 311/44 - Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
• A61K 31/63 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide
• A61P 11/06 - Antiasthmatics

Abstract

aa162bb16b2b166)alkyl group, -CO-NH-, and -NH-CO-, for use for the treatment of cancers, such as metastatic cancers.

IPC Classes  ?

• C07C 311/21 - Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
• C07C 311/44 - Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
• A61P 35/04 - Antineoplastic agents specific for metastasis
• A61K 31/63 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide

Abstract

The present invention concerns a compound having the following formula (VII): wherein: - X' is -S- or -CH2-; - p is an integer comprised between 1 and 3; - Rs is a (Ci-C6)alkyl group; and - R4 groups, identical or different, are chosen from (Ci-C6)alkyl groups for use for the treatment of pathologies characterized by bronchoconstriction.

IPC Classes  ?

• C07C 311/21 - Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
• A61K 31/63 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide
• A61P 11/06 - Antiasthmatics
• C07C 311/44 - Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring

Abstract

The present invention relates to a compound of the following general formula (I): (I) in which: - either R represents a group Ri and R' represents a group -ArCy1, or R represents a group -ArCy1 and R' represents a group R1; R1 especially representing H or a (C1-C6)alkyl group; A1 representing an -NH- radical or an -NH-CH2- radical; Cy1 especially representing a phenyl group, - A represents a (hetero)aromatic fused ring comprising from 5 to 7 atoms, for use thereof for treating cancers.

IPC Classes  ?

• C07D 471/04 - Ortho-condensed systems
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61P 35/00 - Antineoplastic agents
• C07D 239/42 - One nitrogen atom

Abstract

The present invention relates to a compound of the following general formula (I): (I) in which: - either R represents a group Ri and R' represents a group -ArCy1, or R represents a group -ArCy1 and R' represents a group R1; R1 especially representing H or a (C1-C6)alkyl group; A1 representing an -NH- radical or an -NH-CH2- radical; Cy1 especially representing a phenyl group, - A represents a (hetero)aromatic fused ring comprising from 5 to 7 atoms, for use thereof for treating cancers.

IPC Classes  ?

• C07D 471/04 - Ortho-condensed systems
• C07D 239/42 - One nitrogen atom
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to an in vitro method for determining the risk of occurrence of chronic lung graft dysfunction in a human subject comprising: a) measuring the level of CD9+ B cells in a blood sample of the subject, b) comparing the level of CD9+ B cells measured at step a) with one or more reference values of the level of CD9+ B cells, and c) determining the risk of occurrence of chronic lung graft dysfunction in the said subject from the comparison performed at step b).

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

The invention describes a method for obtaining purified recombinant Adeno-Associated Virus particles (rAAV), comprising performing a depth filtration of a starting material previously obtained from cells producing rAAV particles comprising a cell lysate and/or a culture supernatant, followed by a first step of anion-exchange chromatography, a second step of anion-exchange chromatography and a final step of tangential flow filtration, whereby purified recombinant Adeno-Associated Virus particles (rAAV) are provided.

IPC Classes  ?

• C12N 7/02 - Recovery or purification
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• B01D 15/36 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion

Abstract

The present invention relates to the use of insulin-producing cells encapsulated in silanized hydroxypropyl methylcellulose (Si-HPMC) for the treatment of type 1 diabetes. Methods and kits are also provided for restoring and/or maintaining euglycemia in type 1 diabetic patients and in type 1 prediabetic patients.

IPC Classes  ?

• A61L 27/38 - Animal cells
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61K 35/39 - PancreasIslets of Langerhans
• A61K 47/38 - CelluloseDerivatives thereof
• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

The invention relates to a method for the cryopreservation of at least one sample of tumour-infiltrating lymphocytes, comprising the following steps: i) the in vitro culture of tumour-infiltrating lymphocytes using a collection of samples of in-transit skin nodules, ganglion or metastasis, from a patient with a stage III or IV melanoma, said step comprising the emergence of the tumour-infiltrating lymphocytes contained in the sample of in-transit skin nodules, ganglion or metastasis, followed by the stimulation of the tumour-infiltrating lymphocytes resulting from the emergence step, and, subsequently, the amplification of the stimulated tumour infiltrating lymphocytes; ii) the mixing of at least one sample obtained in step (i) with a composition comprising, in a physiologically acceptable medium, a) human albumin serum, b) at least one saccharide, and c) at least two ingredients selected from among DMSO, L-cysteine, coenzyme Q10 and C3-C5 alkanediols; and subsequently iii) the freezing of the mixture obtained in step (ii).

IPC Classes  ?

• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• A01N 1/02 - Preservation of living parts

Abstract

The invention describes a method for obtaining purified recombinant Adeno-Associated Virus particles (rAAV), comprising the steps of: a) performing a depth filtration of a starting material previously obtained from cells producing rAAV particles, the said starting material being selected in a group comprising a cell lysate and a culture supernatant, whereby a rAAV-containing clarified composition is provided; b) submitting the rAAV-containing clarified composition to a first step of anion- exchange chromatography on a chromatographic support wherein elution is performed by using a linear salt gradient and wherein the rAAV-containing fraction is collected, whereby a first rAAV enriched composition is provided; c) submitting the first rAAV enriched composition at least once to a second step of anion-exchange chromatography on a chromatographic support wherein elution is performed by using a linear salt gradient and wherein the rAAV-containing fraction is collected, whereby a second rAAV enriched composition is provided; d) submitting the second rAAV enriched composition to a step of tangential flow filtration, whereby purified recombinant Adeno-Associated Virus particles (rAAV) are provided.

IPC Classes  ?

• C12N 15/864 - Parvoviral vectors
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C12N 7/01 - Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
• C12N 7/02 - Recovery or purification
• C12N 9/16 - Hydrolases (3.) acting on ester bonds (3.1)
• C12N 15/55 - Hydrolases (3)

Abstract

The invention describes a method for obtaining purified recombinant Adeno-Associated Virus particles (rAAV), comprising the steps of: a) performing a depth filtration of a starting material previously obtained from cells producing rAAV particles, the said starting material being selected in a group comprising a cell lysate and a culture supernatant, whereby a rAAV-containing clarified composition is provided; b) submitting the rAAV-containing clarified composition to an affinity purification step, whereby a first rAAV enriched composition is provided; c) submitting the first rAAV enriched composition at least once to: cl) a step of anion-exchange chromatography on a chromatographic support wherein elution is performed by using a salt gradient, preferably a linear salt gradient, and wherein the rAAV-containing fraction is collected, whereby a second rAAV enriched composition is provided; or c2) a step of density gradient centrifugation, wherein the rAAV-containing fraction is collected, whereby a second rAAV enriched composition is provided; d) submitting the second rAAV enriched composition to a step of tangential flow filtration, whereby purified recombinant Adeno-Associated Virus particles (rAAV) are provided.

IPC Classes  ?

• C12N 15/864 - Parvoviral vectors
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C12N 7/01 - Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
• C12N 7/02 - Recovery or purification
• C12N 9/16 - Hydrolases (3.) acting on ester bonds (3.1)
• C12N 15/55 - Hydrolases (3)

Abstract

The invention describes a method for obtaining purified recombinant Adeno-Associated Virus particles (rAAV), comprising the steps of: a) performing a depth filtration of a starting material previously obtained from cells producing rAAV particles, the said starting material being selected in a group comprising a cell lysate and a culture supernatant, whereby a rAAV-containing clarified composition is provided; b) submitting the rAAV-containing clarified composition to an affinity purification step, whereby a first rAAV enriched composition is provided; c) submitting the first rAAV enriched composition at least once to: cl) a step of anion-exchange chromatography on a chromatographic support wherein elution is performed by using a salt gradient, preferably a linear salt gradient, and wherein the rAAV-containing fraction is collected, whereby a second rAAV enriched composition is provided; or c2) a step of density gradient centrifugation, wherein the rAAV-containing fraction is collected, whereby a second rAAV enriched composition is provided; d) submitting the second rAAV enriched composition to a step of tangential flow filtration, whereby purified recombinant Adeno-Associated Virus particles (rAAV) are provided.

IPC Classes  ?

• C12N 7/02 - Recovery or purification
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy

Abstract

The invention describes a method for obtaining purified recombinant Adeno-Associated Virus particles (rAAV), comprising the steps of: a) performing a depth filtration of a starting material previously obtained from cells producing rAAV particles, the said starting material being selected in a group comprising a cell lysate and a culture supernatant, whereby a rAAV-containing clarified composition is provided; b) submitting the rAAV-containing clarified composition to a first step of anion- exchange chromatography on a chromatographic support wherein elution is performed by using a linear salt gradient and wherein the rAAV-containing fraction is collected, whereby a first rAAV enriched composition is provided; c) submitting the first rAAV enriched composition at least once to a second step of anion-exchange chromatography on a chromatographic support wherein elution is performed by using a linear salt gradient and wherein the rAAV-containing fraction is collected, whereby a second rAAV enriched composition is provided; d) submitting the second rAAV enriched composition to a step of tangential flow filtration, whereby purified recombinant Adeno-Associated Virus particles (rAAV) are provided.

IPC Classes  ?

• C12N 7/02 - Recovery or purification
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy

Abstract

The present disclosure relates to novel anti IL-34 antibodies or antigen-binding fragments thereof specifically binding cytokine IL-34 with high affinity, the method of obtaining of these antibodies and their therapeutic use.

IPC Classes  ?

• C07K 14/54 - Interleukins [IL]
• C07K 14/715 - ReceptorsCell surface antigensCell surface determinants for cytokinesReceptorsCell surface antigensCell surface determinants for lymphokinesReceptorsCell surface antigensCell surface determinants for interferons
• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present disclosure relates to novel anti IL-34 antibodies or antigen-binding fragments thereof specifically binding cytokine IL-34 with high affinity, the method of obtaining of these antibodies and their therapeutic use.

IPC Classes  ?

• C07K 14/54 - Interleukins [IL]
• C07K 14/715 - ReceptorsCell surface antigensCell surface determinants for cytokinesReceptorsCell surface antigensCell surface determinants for lymphokinesReceptorsCell surface antigensCell surface determinants for interferons
• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention concerns a method for the in vitro diagnosis of a graft tolerant or non-tolerant phenotype, comprising determining from a grafted subject biological sample an expression profile comprising the 20 following genes: TCL1A, MZB1, CD22, BLK, MS4A1, CD79B, BLNK, FCRL2, IRF4, ID3, AKR1C3, HINT1, RFC4, ANXA2R, CD40, FCER2, CTLA4, AKIRIN2, EPS15 and PLBD1; comparing the obtained expression profile with at least one reference expression profile, and determining the graft tolerant or graft non-tolerant phenotype from said comparison.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

The present invention describes a composition comprising a mixture of human foetal keratinocyte cells and human foetal fibroblast cells, the ratio between said keratinocyte and fibroblast cells ranging from 0.75 to 2.5, preferably being 1:1 or 7:3. This composition is advantageously included in a bandage, said bandage preferably being sterile and packaged in a container impermeable to microorganisms. The present invention finally concerns the use of this composition as a drug, in particular for treating a skin defect (wound, burn or ulcer).

IPC Classes  ?

• A61K 35/36 - SkinHairNailsSebaceous glandsCerumenEpidermisEpithelial cellsKeratinocytesLangerhans cellsEctodermal cells
• A61L 15/32 - Proteins, polypeptidesDegradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
• A61L 15/40 - Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing ingredients of undetermined constitution or reaction products thereof
• A61K 35/33 - Fibroblasts
• A61L 15/44 - Medicaments
• A61K 35/54 - OvariesOvaOvulesEmbryosFoetal cellsGerm cells

Abstract

The present invention relates to a method of predicting delayed graft function (DGF) after kidney transplantation in patient, said method comprising a step of calculating a score (DGFS) based on the following variables: induction therapy, Cold ischemia time (CIT), donor creatinin levels, donor age, and patient BMI. Methods for assessing the need for a DGF therapy after kidney transplantation are disclosed. A processing system including a computation unit and an input interface, characterized in that said system includes means for implementing the method for determining the risk of DGF is also provided.

IPC Classes  ?

• G01N 33/70 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving creatine or creatinine
• G06F 19/00 - Digital computing or data processing equipment or methods, specially adapted for specific applications (specially adapted for specific functions G06F 17/00;data processing systems or methods specially adapted for administrative, commercial, financial, managerial, supervisory or forecasting purposes G06Q;healthcare informatics G16H)

Abstract

The invention relates to methods comprising a step consisting of determining the proportion and/or the level of T regulatory lymphocytes with a CD4+ CD8ααlow Foxp3neg phenotype specific for Faecalibacterium prausnitzii for (i) diagnosing, (ii) prognosing outcome of, or (iii) predicting the risk of developing, an inflammatory bowel disease in a patient. The invention also concerns the treatment of an inflammatory bowel disease. The invention further relates to the kits that are useful in the above methods for diagnosing / prognosing an inflammatory bowel disease, and in the treatment of an inflammatory bowel disease. In a particular embodiment, the inflammatory bowel disease is the Crohn's disease.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The present invention relates to a polypeptide for use as a medicament in the treatment and/or prevention of a disease wherein the RANKL-RANK signaling pathway is involved, in particular a bone resorptive disease.

IPC Classes  ?

• A61K 38/08 - Peptides having 5 to 11 amino acids
• A61K 38/10 - Peptides having 12 to 20 amino acids
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 19/08 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
• A61P 19/10 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
• A61K 38/04 - Peptides having up to 20 amino acids in a fully defined sequenceDerivatives thereof
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates

Abstract

The present invention describes a composition comprising a mixture of human foetal keratinocyte cells and human foetal fibroblast cells, the ratio between said keratinocyte and fibroblast cells ranging from 0.75 to 2.5, preferably being 1 :1 or 7 :3. This composition is advantageously included in a bandage, said bandage preferably being sterile and packaged in a container impermeable to microorganisms. The present invention finally concerns the use of this composition as a drug, in particular for treating a skin defect (wound, burn or ulcer).

IPC Classes  ?

• A61K 35/36 - SkinHairNailsSebaceous glandsCerumenEpidermisEpithelial cellsKeratinocytesLangerhans cellsEctodermal cells
• A61K 35/54 - OvariesOvaOvulesEmbryosFoetal cellsGerm cells
• A61L 15/40 - Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing ingredients of undetermined constitution or reaction products thereof
• A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Abstract

The present invention describes a composition comprising a mixture of human foetal keratinocyte cells and human foetal fibroblast cells, the ratio between said keratinocyte and fibroblast cells ranging from 0.75 to 2.5, preferably being 1 :1 or 7 :3. This composition is advantageously included in a bandage, said bandage preferably being sterile and packaged in a container impermeable to microorganisms. The present invention finally concerns the use of this composition as a drug, in particular for treating a skin defect (wound, burn or ulcer).

IPC Classes  ?

• A61K 35/36 - SkinHairNailsSebaceous glandsCerumenEpidermisEpithelial cellsKeratinocytesLangerhans cellsEctodermal cells
• A61K 35/54 - OvariesOvaOvulesEmbryosFoetal cellsGerm cells
• A61L 15/40 - Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing ingredients of undetermined constitution or reaction products thereof
• A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Abstract

The present invention relates to the use of an hydrogel comprising silylated biomolecule for the three-dimensional culture of cardiomyocytes or stem cells which are able to differentiate into cardiomyocytes, and to an aqueous composition comprising i) cardiomyocytes or stem cells which are able to differentiate into cardiomyocytes, and ii) a hydrogel comprising silylated biomolecule, for use for treating heart failure, in particular heart failure following myocardial infarction.

IPC Classes  ?

• A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• A61K 47/38 - CelluloseDerivatives thereof
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
• A61K 35/34 - MusclesSmooth muscle cellsHeartCardiac stem cellsMyoblastsMyocytesCardiomyocytes
• A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells

Abstract

The present invention concerns materials and methods for characterizing monoclonal immunoglobulin specificity of a Monoclonal Gammopathy of Undetermined Significance (MGUS) or Myeloma patients using a protein microarray comprising (a) a substrate, (b) antigens immobilized on the substrate, said antigens being selected from a defined group consisting of infectious agent antigens and/or self-antigens. In particular said protein microarray may be used to improve diagnosis, for the prognosis of myeloma or MGUS, for preventing transformation of MGUS toward myeloma, for adapting treatment of MGUS and myeloma or for monitoring the response to therapy of MGUS and myeloma patients.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• C40B 40/00 - Libraries per se, e.g. arrays, mixtures
• G01N 33/576 - ImmunoassayBiospecific binding assayMaterials therefor for hepatitis

Abstract

The present invention relates to a method for determining whether a cytomegalovirus infection in a transplanted patient is susceptible to induce allograft rejection comprising detecting the presence of at least one HLA-E-restricted CD8 αβ T cell population displaying reactivity against peptides derived from the leader sequences of both HCMV-UL40 protein and allogeneic classical HLA-I molecules in a blood sample of the patient, wherein the presence of said populations indicated that the cytomegalovirus infection in the transplant patient is susceptible to induce allograft rejection.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

The present invention concerns radioactive rhodium complexes, their preparation methods, and their use for the radiolabelling of biomolecules, especially monoclonal antibodies.

IPC Classes  ?

• C07F 15/00 - Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
• A61K 31/24 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to a polypeptide for use as a medicament in the treatment and/or prevention of a disease wherein the RANKL-RANK signaling pathway is involved, in particular a bone resorptive disease.

IPC Classes  ?

• A61K 38/04 - Peptides having up to 20 amino acids in a fully defined sequenceDerivatives thereof
• A61P 19/00 - Drugs for skeletal disorders
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof

Abstract

The present invention relates to a polypeptide for use as a medicament in the treatment and/or prevention of a disease wherein the RANKL-RANK signaling pathway is involved, in particular a bone resorptive disease.

IPC Classes  ?

• A61K 38/04 - Peptides having up to 20 amino acids in a fully defined sequenceDerivatives thereof
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• A61P 19/00 - Drugs for skeletal disorders

Abstract

The present invention relates to the use of an hydrogel comprising silylated biomolecule for the three-dimensional culture of cardiomyocytes or stem cells which are able to differentiate into cardiomyocytes, and to an aqueous composition comprising i) cardiomyocytes or stem cells which are able to differentiate into cardiomyocytes, and ii) a hydrogel comprising silylated biomolecule, for use for treating heart failure, in particular heart failure following myocardial infarction.

IPC Classes  ?

• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells

Abstract

The present invention relates to an in vitro method for diagnosing the infectious state of an individual on the basis of a sample of white corpuscles arising from a biological specimen taken from an organ potentially infected by a pathogenic micro-organism of said individual, comprising at least the following two steps: i) measuring the mean cellular intensity of the autofluorescence of said sample, and ii) comparing the intensity measured in step i) with a control value, so as to determine the infectious state of said individual. The diagnostic method of the invention uses a routine optical material making it possible to work in wavelength regions which are compatible with the cellular autofluorescence, and thus constitutes a rapid, reliable and inexpensive aid for the diagnosis or monitoring of an infection in an individual.

IPC Classes  ?

• G01N 21/64 - FluorescencePhosphorescence

Abstract

The present invention relates to an in vitro method for diagnosing the infectious state of an individual on the basis of a sample of white corpuscles arising from a biological specimen taken from an organ potentially infected by a pathogenic micro-organism of said individual, comprising at least the following two steps: i) measuring the mean cellular intensity of the autofluorescence of said sample, and ii) comparing the intensity measured in step i) with a control value, so as to determine the infectious state of said individual. The diagnostic method of the invention uses a routine optical material making it possible to work in wavelength regions which are compatible with the cellular autofluorescence, and thus constitutes a rapid, reliable and inexpensive aid for the diagnosis or monitoring of an infection in an individual.

IPC Classes  ?

• G01N 15/05 - Investigating sedimentation of particle suspensions in blood

Abstract

Bone regeneration membrane (1) comprising: a dense layer (2) made of resorbable polymer, said dense layer (2) having first and second opposite surfaces and being adapted to form a barrier to cells and soft tissues, a nanofibrillar layer (3) made of resorbable polymer and attached to the first surface of the dense layer (2), said nanofibrillar layer comprising fibers having a diameter of nanometer size, said fibers being interlaced so as to present an average pore size greater than 10 μm to allow cell permeability and bone tissue regeneration, the nanofibrillar layer (3) having a permeability κ between 0.4 * 10-9 m2 and 11 * 10-9 m2, preferably between 1 * 10-9 m2 and 4 * 10-9 m2, in particular substantially of 2 * 10-9 m2..

IPC Classes  ?

• A61L 31/14 - Materials characterised by their function or physical properties

Abstract

The present invention relates to a method for detecting the presence or the absence, and optionally quantifying and/or isolating, antigen-specific peripheral blood mononuclear cells. This method, which involves flow cytometry, is based on the use of a fluorescently- labeled antibody specifically recognizing peripheral blood mononuclear cells, and of fluorescently-labeled beads coated with at least one antigen that is specifically recognized by antigen-specific peripheral blood mononuclear cells. The method according to the invention is for example useful for diagnosing immune disorders such as transplant rejections and autoimmune disorders.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

The invention relates to a method of in-vitro evaluation of the physiological state of a gastric mucous membrane on the basis of exfoliated cells isolated from a biological fluid of a human or nonhuman animal individual, according to which said cells are subjected to a set of antibodies able to interact with protein markers from among at least one autophagia marker and at least one clock marker. Advantageously, anti-SURVIVIN antibodies and/or anti-LC3 antibodies are used as autophagia markers. Likewise, anti-PERIOD1 antibodies and/or anti-CLOCK antibodies are used as clock markers. The invention also relates to a kit comprising a set of antibodies capable of being used for said method.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present invention relates to a compound having formula (I): wherein: - X is in particular 125I Or 211At; - R1 and R'1 are independently from each other chosen preferably from the group consisting of electron-withdrawing groups and alkyl groups; - R2 is chosen from the group consisting of : H, alkyl groups, functional groups being able to bind a vector, and functional groups having targeting properties which make the compound of the invention a vector itself; - Z is a heteroatom, - R5, R8 and R9 are preferably H; - Y is preferably an electron withdrawing group.

IPC Classes  ?

• C07B 59/00 - Introduction of isotopes of elements into organic compounds

Abstract

The invention concerns: - a silylated biomolecule having the following formula (I): - the process for the preparation of a silylated biomolecule of formula (I), - the use of a silylated biomolecule of formula (I) to functionalize the surface of a support, - a process for the preparation of a hydrogel by use of a silylated biomolecule of formula (I), - the hydrogel obtainable by said process, - said hydrogel as a biological tissue substitute, - a composition comprising said hydrogel in a pharmaceutically acceptable vehicle, - said composition for the release of active principle.

IPC Classes  ?

• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
• C07F 7/18 - Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages

Abstract

The present invention relates to a pharmaceutical composition that includes at least one agonist of at least one receptor of the ToII type (TLR) selected from TLR 4 and 9, and to be used in the prophylactic treatment of septic complications of post-traumatic systemic immune depression in a patient suffering from one or more severe traumas and hospitalized, in particular in a hospital resuscitation ward. Said TLR 4 agonist is preferably the monophosphoryl lipid A (MPLA) or the 3-0 deacylated monophosphoryl lipid A (3D-MPLA), and said TLR 9 agonist is a CpG oligodeoxynucleotide (CpG ODN).

IPC Classes  ?

• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants

Abstract

The invention relates to a method for determining a risk of permanent rejection of a graft after being transplanted to a recipient, said method being characterized in that it includes the following steps: (a) entering physiological/clinical characteristics of the recipient and the donor into a computation unit by means of an input interface, said characteristics including the gender of the recipient, the creatinine level of the graft donor when sampled, the age of the recipient at the time of the transplant, -the number of renal transplants previously received by the recipient, - a creatinine level of the recipient measured twice at at least one predetermined point in time after the transplant, a proteinuria level of the recipient measured at a predetermined point in time after the transplant, and the existence of an episode of permanent rejection of the transplant during the first year of the transplant; (b) determining the parameters on the basis of said characteristics; (c) combining said parameters so as to obtain a risk score of permanent rejection of the graft; and (d) analyzing said risk score so as to determine a risk of permanent rejection of a graft.

IPC Classes  ?

• G06F 19/00 - Digital computing or data processing equipment or methods, specially adapted for specific applications (specially adapted for specific functions G06F 17/00;data processing systems or methods specially adapted for administrative, commercial, financial, managerial, supervisory or forecasting purposes G06Q;healthcare informatics G16H)

Abstract

The invention relates to 5'-adenosine monophosphate-activated protein kinase (AMPK) activators such as biguanide derivatives and 5-aminoimidazole-4-carboxamide riboside (AICAR) or derivatives thereof for use in preventing and/or treating pulmonary hypertension.

IPC Classes  ?

• A61K 31/155 - Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (HN=C(OH)NH2), isothiourea (HN=C(SH)—NH2)
• A61K 31/7056 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
• A61P 9/12 - Antihypertensives

Abstract

The present invention relates to the identification and use of protein biomarkers with clinical relevance to kidney status and chronic renal injury or disorder. In particular, the invention provides the identity of marker proteins which are recognized by antibodies present in patients suffering from end-stage renal disorder, stable renal transplant, renal transplant glomerulopathy (TG), and interstitial fibrosis and tubular atrophy (IFTA). Methods and kits are described for using these proteins in the study and diagnosis of chronic renal transplant injury, and in the selection and/or monitoring of treatment regimens.

IPC Classes  ?

• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present invention relates to novel melanoma antigen peptides and specific T lymphocytes directed to said peptides and the use thereof for treating melanoma.

IPC Classes  ?

• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The present invention relates to hydroxy-bisphosphonic acid derivatives corresponding to general formula (I): in which: - n and m denote, independently of one another, an integer ranging from 1 to 4, - X denotes an oxygen atom or an N-R3 group, - R1 and R3 denote, independently of one another, a linear or branched C1 to C6 alkyl group, and - R2 denotes a residue of a molecule of therapeutic or diagnostic interest, or pharmaceutically acceptable salts of said derivatives, and also the method for the preparation thereof and the therapeutic or diagnostic use thereof.

IPC Classes  ?

• C07F 9/38 - Phosphonic acids [R—P(:O)(OH)2]Thiophosphonic acids
• A61K 31/663 - Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
• A61P 3/14 - Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
• A61P 19/10 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to a method for preparing a hydroxy-bisphosphonic acid derivative or a salt thereof, from the corresponding carboxylic acid, comprising the following steps: - activation of the carboxylic acid function in the form of the boronate derivative thereof through the action of a borane, then - reaction with tris(trimethyl­silyl)phosphite, under Arbuzov conditions - treatment with an alcohol, chosen in particular from an aliphatic alcohol or trifluoromethanol, and - separation of the hydroxy-bisphosphonic acid derivative formed, from the reaction medium.

IPC Classes  ?

• C07F 9/38 - Phosphonic acids [R—P(:O)(OH)2]Thiophosphonic acids

Abstract

The present invention relates to hydroxy-bisphosphonic acid derivatives corresponding to general formula (I): in which: - n and m denote, independently of one another, an integer ranging from 1 to 4, - X denotes an oxygen atom or an N-R3 group, - R1 and R3 denote, independently of one another, a linear or branched C1 to C6 alkyl group, and - R2 denotes a residue of a molecule of therapeutic or diagnostic interest, or pharmaceutically acceptable salts of said derivatives, and also the method for the preparation thereof and the therapeutic or diagnostic use thereof.

IPC Classes  ?

• C07F 9/38 - Phosphonic acids [R—P(:O)(OH)2]Thiophosphonic acids
• A61K 31/663 - Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
• A61P 35/00 - Antineoplastic agents
• A61P 19/10 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
• A61P 3/14 - Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis